
Healthcare · BSE
Himalaya Nutravedics India Ltd is engaged in the manufacturing, marketing, and distribution of Ayurvedic and nutraceutical formulations in India, along with offering third-party contract manufacturing services for other companies in this space. The company has a diversified product portfolio comprising classical Ayurvedic formulations based on traditional texts, proprietary Ayurvedic products, and nutraceutical supplements, available in various dosage forms such as soft gelatin capsules, hard gelatin capsules, tablets, liquid orals, and medicated oils. It operates on a hybrid business model that balances its own branded products with contract manufacturing, supported by an integrated in-house manufacturing facility located in Hyderabad, Telangana. As of September 2025, its products are distributed across multiple states including Telangana, Andhra Pradesh, Kerala, Gujarat, and Uttar Pradesh, with offerings catering to a wide range of wellness segments such as digestive health, immunity, metabolic health, joint care, reproductive health, respiratory wellness, pain management, and overall well-being, aligned with regulatory standards.
Price Band
₹100 – ₹106
Issue Size
₹249.96 L Cr
Lot Size
1200 shares
GMP
Est. Listing
₹106
at current GMP
Subscribed
2.33x
overall
Open
22 Sep 2026
Close
24 Sep 2026
Allotment
25 Sep 2026
Refund
26 Sep 2026
Demat Credit
27 Sep 2026
Listing
29 Sep 2026
Designated Registrar: Kfin Technologies Limited
Allotment Date
25 Sep 2026
Basis finalization
Refunds Initiate
26 Sep 2026
Mandate release
Demat Credit
27 Sep 2026
Shares in demat
Listing Debut
29 Sep 2026
Trading begins
Himalaya Nutravedics India Limited is bringing an initial public offering (IPO) in the Healthcare sector with an aggregate issue size of ₹24,99,600 Crores. The shares are offered at a price band of ₹100 to ₹106 per equity share on BSE. Currently, market analysts recommend evaluating the company's financial valuation, price-to-earnings (P/E) multiple, and peer comparison prior to submitting bids.
The public offer consists of a fresh issue and offer-for-sale structured under SEBI regulations. Bidding is open to Qualified Institutional Buyers (QIB), Non-Institutional Bidders (NII/HNI), and Retail Individual Investors (RII). Applications can be submitted online using ASBA or UPI mandate through certified stock brokers and net banking portals.
Following the close of bidding on 2026-09-24, the basis of allotment is scheduled to be finalized on 2026-09-25. Investors can verify their application status online by submitting their PAN card number, Application Number, or DP Client ID on the registrar's official portal (Kfin Technologies Limited) or the BSE allotment checking window.
Allotment records are updated in batches. If the status is not yet available, please wait a few hours until the basis of allotment is fully finalized.
Since funds are blocked under ASBA/UPI, the bank will automatically release the blocked hold on your funds upon receipt of revocation instructions from the sponsor bank.